



Therapeutic Efficacy of Methanol Extract of *Bidens tripartita* in HT22 Cells by Neuroprotective Effect

Yerim Son¹ and Choong Je Ma^{1,2,*}

¹Department of Medical Biomaterials Engineering, College of Biomedical Sciences, Kangwon National University, Chuncheon 24341, South Korea

²Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon 24341, South Korea

Abstract – Oxidative stress brings about apoptosis through various mechanisms. In particular, oxidative stress in neuronal cells can cause a variety of brain diseases. This study was conducted to investigate the effect of *Bidens tripartita* on oxidative stress in neuronal cells. *B. tripartita* has traditionally been used in Russia as a medicine for diseases such as rhinitis, angina and colitis. Over-production of glutamate induces oxidative stress. When the oxidative stress occurs in the cells, reactive oxygen species (ROS) and Ca²⁺ increase. In addition, the abrupt decline of mitochondrial membrane potential and the decrease of glutathione related enzymes such as glutathione reductase (GR) and glutathione peroxidase (GPx) are also observed. The samples used in the experiment showed cytoprotective effect in the MTT assay. It also lowered the ROS and Ca²⁺ level, and increased degree of mitochondrial membrane potential, GR and GPx. As a result, *B. tripartita* had a positive effect against oxidative stress. Thus, it is expected to have potential for treatment and prevention of degenerative brain diseases such as Alzheimer's disease.

Keywords – *Bidens tripartite*, Alzheimer's disease, HT22 cell, Oxidative stress, Glutathione

Introduction

Alzheimer's Disease (AD) is the most common form of dementia, a neurodegenerative disease.¹ This disease is accompanied by memory and behavioral disorders. Causes of AD include various biological processes such as abnormal deposition of amyloid-beta (A β) peptide, accumulation of neurofibrillary tangles (NFTs), deficiency or insufficient synthesis of neurotransmitters, oxidative stress, and genetic and environmental factors.² Glutamate is an excitatory neurotransmitter that is present in the central nervous system and affects memory and learning abilities.^{3,4} Glutamate overdose in vivo contributes to brain damage.⁵ Under conditions that can damage the brain, such as hypoxia, the glutamate concentration in the brain increases up to 50 times.⁶ Glutamate in the brain with increased concentration is a cause of degenerative brain disease. Glutamate over expression increases the production of reactive oxygen species (ROS) in the cell and results in apoptosis.⁷ Glutathione (GSH) plays a role in

cushioning ROS, and consists of glutamate, cysteine, glycine.⁸ Glutamate makes glutathione (GSH) and activity of glutathione reductase (GR), glutathione peroxidase (GPx) which plays an important role in GSH's mechanisms decrease.⁹ It also causes mitochondrial dysfunction and excessively increases Ca²⁺ concentration.¹⁰ These phenomena lead to oxidative stress causing to cell damage. In addition, damage to cells in neuronal cells can lead to degenerative diseases. Overall, oxidative stress and excess glutamate can contribute to the development and progression of neurological diseases, making them important targets for therapeutic intervention.

Bidens tripartita has traditionally been used in Russia as a medicine for diseases such as rhinitis, angina and colitis and it also became a material for the treatment of dysentery herbal medicine.¹¹ *B. tripartita*, an annual plant of Asteraceae, contains components such as flavonoids, coumarins, polysaccharides and carotenoids.¹² From these, we supposed that *B. tripartita* has anti-inflammatory effect. Reducing neuroinflammation is a promising therapeutic strategy for Alzheimer's disease. Various anti-inflammatory drugs and natural compounds have been investigated for their potential to reduce neuroinflammation and improve cognitive function in AD.¹³ In this

*Author for correspondence

Choong Je Ma, Ph.D., Department of Medical Biomaterials Engineering, College of Biomedical Science, Kangwon National University, Kangwondaehak-gil 1, Chuncheon 24341, Republic of Korea
Tel: +82-33-250-6565; E-mail: cjma@kangwon.ac.kr

study, we have examined the effects of *B. tripartita* as a natural treatment for AD through several activity experiments.

Natural products have infinite possibilities to contain unknown compounds, including already known compounds. The treatment of disease using natural product has been studied steadily. The use of natural products is less of a side effect than using compounds obtained through synthesis. Indeed, natural products are in many cases an important source of bioactive materials as therapeutic agents.¹⁴ We conducted experiments to determine the possibility that *B. tripartita* could be used for the treatment and prevention of degenerative brain disease such as AD.

Experimental

Plant materials and extract preparation – The dried leaves of *Bidens tripartita* were purchased from kyung-dongmarket (Seoul, Korea). The leaves of *B. tripartita* were extracted with 80% MeOH by 9 times for 60 min with ultrasonicator. The extract was concentrated under reduced pressure and obtained a solid form.

Cell culture and *in vitro* test reagents – Dulbecco's modified eagle's medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, Hank's balanced salt solution and trypsin- EDTA for cell culture were purchased from Gibco BRL Co, (U.S.A). Glutamate, 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMSO, sodium bicarbonate (NaHCO₃), HEPES, 2',7'-dichlorofluorescein, L-GSH reduced, L-GSH oxidized, hydrogen peroxide solution, rhodamine 123, 5',5'-dithiobis (2-nitrobenzoic acid) and triton X-100 were obtained from sigma (U.S.A). Fura 2-AM was purchased from Dojindo (U.S.A). 0.2 µm membrane filter was purchased from ADVANTEC in Japan.

Cell culture – HT22 cell line derived from mouse hippocampus was used for the experiment. Cell viability was measured in glutamate-induced apoptosis using HT22 cells. Cells were cultured in DMEM containing 10% (v/v) fetal bovine serum (FBS), 1% penicillin/streptomycin, NaCO₃ (2 mg/mL), and 15 mM HEPES, and incubated at 37 °C humidified with 5% CO₂.

Cell viability – HT22 cells were seed at 1.7×10^4 /well in 48-well plates and cultured for 24 h (at 37 °C, humidified 5% CO₂). For the control and negative control groups, add 300 µl of DMEM, 300 µl of trolox for positive control. The remaining wells receive 300 µl of diluted *B. tripartita* extract. (1, 20, 50 µg/mL). After 1 h

incubation, all wells except control group are treated with 3 mM glutamate and 300 µl of DMEM was added to control group and all cells were incubated. After 23 h, 1 µg/mL MTT solution was treated to each well for 3 h and MTT formazan was dissolved by dimethyl sulfoxide (DMSO). The optical density (OD) was measured using an ELISA at 570 nm. The neuroprotective activity of samples was determined by relative protection (%); Relative protection = (OD of glutamate-treated with sample group – OD of only glutamate-treated group)/(OD of control group – OD of only glutamate-treated group) × 100.

Measurement of intracellular ROS levels – The cultured HT22 cells were treated with glutamate, trolox, samples which were diluted *B. tripartita* extract and cultured at 37 °C. After 8 h, 40 µl of 100 µM DCF-DA was added and cultured for 1 h. After that, the medium was removed and dissolved in 300 µl of 1.0% triton X-100 for 15 min at 37 °C. Fluorescence was measured twice at excitation wavelength (490 nm), emission wavelength (525 nm).

Measurement of Ca²⁺ levels – The cultured HT22 cells were treated with trolox and samples which were diluted *B. tripartita* extract, and 10 µl of 20 µM Fura-AM was added to all wells. After incubation for 1 h, glutamate was treated and cultured at 37 °C for 2 h. After incubation, the medium was removed and dissolved in 150 µl of 1.0% Triton X-100 at 37 °C for 15 min. Fluorescence was measured twice in calcium complex (340 nm), calcium free (510 nm).

Measurement of mitochondrial membrane potential – The cultured HT22 cells were treated with each concentration of samples which were diluted *B. tripartita* extract and added to 3 mM glutamate for 1 h to induce apoptosis. 10 µl of Rhodamine123 was added, incubated at 37 °C for 30 min, and washed three times with PBS. Fluorescence is measured twice at extraction wavelength (480 nm), emission wavelength (525 nm).

Measurement of glutathione reductase and glutathione peroxidase – The cultured HT22 cells were treated with glutamate, trolox and *B. tripartita* extract at different concentrations. After 8 h, it was washed with phosphate buffer solution of 0.2 M, pH 7.4. After that, the washed cells were dissolved with sulfosalicylic acid, centrifuged (at 4 °C, for 30 min, 3000 g) and the supernatant was collected. GR is an enzyme that catalyzes the reduction of glutathione disulfide (GSSG) to GSH in a NADPH dependent manner. Therefore, GR was measured as the amount of GSSG reduced in the presence of NADPH. Conversely, GPx was tested using the degree of oxidation of GSH to GSSG. The results of experiments were

recorded as absorbance at 340 nm.

Statistical analysis – The data of experiments were presented as mean \pm SD, respectively. All experimental results were statistically analyzed using one-way ANOVA and Tukey's post hoc test with IBM SPSS Statistics software V26 (IBM, Armonk, NY, US) and Microsoft Excel software (Microsoft). The differences between the experimental groups were significant at $p < 0.05$, 0.01 and 0.001 level, respectively.

Results and discussion

HT22 cells, a hippocampus-derived cell line used in CNS-related experiments was determined as an experimental subject. We used glutamate and trolox, mechanisms already known to study the cytoprotective activity of *B. tripartita*. Elevation of glutamate causes oxidative stress and apoptosis.¹⁵ Neuronal cell death may lead to memory and learning disorders and ultimately to neurodegenerative brain diseases.¹⁶ We investigated the cytoprotective effects of *B. tripartita* on glutamate-induced neurotoxicity through the MTT assay. These experiments confirmed that *B. tripartita* has cell protective effect on glutamate-induced cytotoxicity in HT22 cells. Low concentration of *B. tripartita* had similar protective effect as glutamate used as a negative control. In HT22 cell, neuroprotective effect of *B. tripartita* was detected on

glutamate-induced cytotoxicity (Fig. 1). The study showed that about 65.42% of cells subjected to glutamate injury remained viable compared to untreated cells. However, pretreatment with increasing doses of *B. tripartita* (10, 20, and 50 $\mu\text{g/mL}$) gradually improved cell viability in a dose-dependent manner. At concentrations of 20 and 50 $\mu\text{g/mL}$, *B. tripartita* exhibited a significant neuroprotective activity, with relative protective percentages of 32.15% and 70.28%, respectively. Notably, at a concentration of 50 $\mu\text{g/mL}$, *B. tripartita* exhibited the most potent neuroprotective activity, similar to that of the positive control, trolox.

Overflowing of glutamate causes accumulation of ROS.⁷ We confirm the degree of inhibition of ROS through fluorescence measurement (Fig. 2). A control treated group was rated as 0% and a group of glutamate treated was rated as 100%. Trolox lowered the ROS level to $14.88 \pm 1.81\%$. 10 $\mu\text{g/mL}$ *B. tripartita* increases the ROS level as much as the result of the negative control, $94.84 \pm 2.25\%$. In concentration of 20 $\mu\text{g/mL}$, the ROS level decreased but that was only marginal to $84.24 \pm 1.81\%$. Highest concentration of *B. tripartita*, 50 $\mu\text{g/mL}$, made ROS level low significantly. The antioxidative effect of *B. tripartita* was found to be almost the same as that of trolox at the highest concentration. In the human body, ROS is produced due to various stresses. ROS in the brain may lead to degenerative brain diseases such as AD.¹⁷




Fig. 1. The relative protection of *B. tripartita* against glutamate induced toxicity in HT22 cells. Cells were pretreated with 10, 20, and 50 $\mu\text{g/mL}$ of *B. tripartita* and trolox as positive control. Then 3 mM glutamate was treated after 1 h. Each bar represents the Mean \pm S.D. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus glutamate injured cells.




Fig. 2. The intracellular ROS amount of *B. tripartita* against glutamate toxicity in HT22 cells. Cells were pretreated with 10, 20, and 50 µg/mL of *B. tripartita* and trolox as positive control. Then 3 mM glutamate was treated after 1 h. Each bar represents the Mean \pm S.D. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus glutamate injured cells.

These ROS can be controlled through balance with antioxidants. We examined whether *B. tripartita* functions as an antioxidant to affect the reduction of ROS. Low concentration of *B. tripartita* did not seem to have contributed to the reduction of ROS in the outcome. However, as the concentration of ROS decreased rapidly at high concentration, the antioxidant effect was increased and the amount of ROS decreased.

Oxidative stress and Ca^{2+} are strongly associated with glutamate-induced apoptosis.¹⁸ Glutamate increases the uptake of Ca^{2+} through the activation of the NMDA receptor, Ca^{2+} membrane channel, leading to cell death.¹⁹ Compared with the result of glutamate, *B. tripartita* samples showed significant results from 20 µg/mL to high concentrations. It was less than trolox, the high-concentration sample was as effective as trolox. It was only about 7% different from trolox. Thus, we can confirm that *B. tripartita* was effective in lowering the rate of Ca^{2+} growth due to glutamate. Glutamate makes Ca^{2+} concentration increase. Cells that did not process anything were set to 0%, glutamate treated cells were set at 100% as the standard. The level of fluorescence was $14.88 \pm 1.81\%$ at trolox treated cells. At lowest concentration, 10 µg/mL, the calcium level was not as great as $82.90 \pm 2.64\%$. But the higher concentration, the greater cell protection effect. At concentration of 20 µg/mL, cell protection did not show a strong effect at $44.84 \pm 2.8\%$

but was more effective at 10 µg/mL. And the result of highest concentration was similar with positive control, $24.67 \pm 1.1\%$. As a result, significantly cell protection effect was observed at 20 µg/mL and 50 µg/mL (Fig. 3).

Mitochondrial membrane potential is thought to be related to necrosis or apoptosis, and many researchers are studying the relationship between mitochondria and cell survival.²⁰ Glutamate causes an immediate decrease in mitochondrial membrane potential.²¹ We conducted an experiment to determine the effect of *B. tripartita* on glutamate-induced mitochondrial membrane potential changes. As with previous experiments, low concentration of *B. tripartita* did not show any significant effect. However, the higher concentration, the less decreased in mitochondrial membrane potential. At high concentration, there was no strong effect on the increase of mitochondrial membrane potential, but it showed significant results. Through our experiment, we confirmed that *B. tripartita* had a cytoprotective effect against the mechanisms leading to glutamate-induced depolarization of mitochondrial membrane potential. Glutamate reduced mitochondrial membrane potential. We detected the protection degree of *B. tripartita* in HT22 cells (Fig. 4). Trolox has a protective effect against glutamate induced mitochondrial membrane potential reduction. As a result, in trolox treated cells, mitochondrial membrane potential was decreased to $92.26 \pm 2.33\%$. *B. tripartita* at 10 µg/mL had no obvious




Fig. 3. The intracellular Ca^{2+} amount of *B. tripartita* against glutamate toxicity in HT22 cells. Cells were pretreated with 10, 20, and 50 $\mu\text{g/mL}$ of *B. tripartita* and trolox as positive control. Then 3 mM glutamate was treated after 1 h. Each bar represents the Mean \pm S.D. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus glutamate injured cells.




Fig. 4. The mitochondrial membrane potential level of *B. tripartita* against glutamate toxicity in HT22 cells. Cells were pretreated with 10, 20, and 50 $\mu\text{g/mL}$ of *B. tripartita* and trolox as positive control. Then 3 mM glutamate was treated after 1 h. Each bar represents the Mean \pm S.D. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus glutamate injured cells.

effect to $9.74 \pm 0.55\%$. But the concentration of *B. tripartita* was higher, the mitochondrial membrane potential level increased. At the concentration of 20 $\mu\text{g/mL}$, mitochondrial membrane potential was $47.00 \pm 1.2\%$ and at 50 $\mu\text{g/mL}$, mitochondrial membrane potential was 61.89

$\pm 0.17\%$. The result of the highest concentration had a greatest effect in *B. tripartita* but it was not so effective.

The decrease in glutathione reductase (GR) and glutathione peroxidase (GPx) leads to depletion of glutathione, which inhibits the entry of cysteine into cells




Fig. 5. The glutathione related assays of *B. tripartita* against glutamate toxicity in HT22 cells. GR enzyme activity (A) and GPx enzyme activity (B) was measured. Cells were pretreated with 10, 20, and 50 µg/mL of *B. tripartita* and trolox as positive control. Then 3 mM glutamate was treated after 1 h. Each bar represents the Mean \pm S.D. of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ versus glutamate injured cells.

and causes neuronal cell death.²² Glutamate causes the decrease of GR, GPx and obstructs generation of glutathione. We experimented about how *B. tripartita* affects the activity of GR and GPx. Low concentration of *B. tripartita* did not have a much effect in both GR, GPx. The concentration higher, the activity increased. Especially in GPx, the relative activity increased about three times

when increased at high concentration. It was also found that the highest concentration of both GR and GPx was significant. As a result of two experiments showed that *B. tripartita* increased the activity of GR and GPx against glutamate-induced stress and consequently could prevent the decrease of glutathione. We detected *B. tripartita*'s effect on GR and GPx (Fig. 5). GR and GPx are enzymes

that play an important role in glutathione production³. Glutamate overflowed made GR and GPx activity decrease. At concentration of 10 µg/mL, *B. tripartita* had only 9.07 ± 4% cell protection effect on GR and 4.38 ± 3.34% on GPx. The higher the concentration of *B. tripartita*, the stronger cytoprotective effect. At 20 µg/mL, it showed 28.58 ± 1.94%, 15.86 ± 2.22% cell protective activity in GR and GPx, respectively. *B. tripartita* of 50 µg/mL did not reach trolox but had relatively high protective activity, 50.39 ± 4.74%, 44.77 ± 3.67% each.

In conclusion, we have confirmed that *B. tripartita* has cytoprotective effects in experiments. It was also found that ROS and Ca²⁺ were decreased and mitochondrial membrane potential, activities of GR, GPx were increased. Previous studies shown that *B. tripartita* contains flavonoids, such as 7-*O*-glucosides of isookanin and luteolin.¹¹ Flavonoids are secondary metabolites of plants and fungi. This compound has an antioxidant effect, which seems to be the results of *B. tripartite*.²³ These results suggest that *B. tripartita* may have potential for the prevention and treatment of degenerative brain diseases by reducing apoptosis and protecting neuronal cells from oxidative stress.

Conflict of interest

The authors have declared no conflict of interest.

References

- (1) Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. *Redox Biol.* **2018**, *14*, 450–464.
- (2) Shal, B.; Ding, W.; Ali, H.; Kim, Y. S.; Khan, S. *Front. Pharmacol.* **2018**, *9*, 548.
- (3) Kang, Y.; Tiziani, S.; Park, G.; Kaul, M.; Paternostro, G. *Nat. Commun.* **2014**, *5*, 3672.

- (4) Wang, R.; Reddy, P.H. *J. Alzheimers Dis.* **2017**, *57*, 1041–1048.
- (5) Maily, F.; Marin, P.; Israël, M.; Glowinski, J.; Prémont, J. *J. Neurochem.* **1999**, *73*, 1181–1188.
- (6) Parfenova, H.; Basuroy, S.; Bhattacharya, S.; Tcheranova, D.; Qu, Y.; Regan, R. F.; Leffler, C. W. *Am. J. Physiol. Cell Physiol.* **2006**, *290*, C1399–C1410.
- (7) Amin, F. U.; Shah, S. A.; Kim, M. O. *Sci. Rep.* **2017**, *7*, 40753.
- (8) Zhu, Y.; Carvey, P. M.; Ling, Z. *Brain Res.* **2006**, *1090*, 35–44.
- (9) Kim, S. J.; Jung, H. J.; Hyun, D. H.; Park, E. H.; Kim, Y. M.; Lim, C. J. *Biochimie* **2010**, *92*, 927–932.
- (10) Pivovarova, N. B.; Andrews, S. B. *FEBS J.* **2010**, *277*, 3622–3636.
- (11) Pozharitskaya, O. N.; Shikov, A. N.; Makarova, M. N.; Kosman, V. M.; Faustova, N. M.; Tesakova, S. V.; Galambosi, B. *Phytomedicine* **2010**, *17*, 463–468.
- (12) Tomczykowa, M.; Tomczyk, M.; Jakoniuk, P.; Tryniszewska, E. *Folia Histochem. Cytobiol.* **2008**, *46*, 389–393.
- (13) Kinney, J. W.; Bemiller, S. M.; Murtishaw, A. S.; Leisgang, A. M.; Salazar, A. M.; Lamb, B. T. *Alzheimers Dement (N Y)*. **2018**, *4*, 575–590.
- (14) Villa, F. A.; Gerwick, L. *Immunopharmacol. Immunotoxicol.* **2010**, *32*, 228–237.
- (15) Penugonda, S.; Mare, S.; Goldstein, G.; Banks, W. A.; Ercal, N. *Brain Res.* **2005**, *1056*, 132–138.
- (16) Lefort, J. M.; Vincent, J.; Tallot, L.; Jarlier, F.; De Zeeuw, C. I.; Rondi-Reig, L.; Rochefort, C. *Nat. Commun.* **2019**, *10*, 2251.
- (17) Barzegar, A.; Moosavi-Movahedi, A. A. *PLoS One.* **2011**, *6*, e26012.
- (18) Tang, T. S.; Slow, E.; Lupu, V.; Stavrovskaya, I. G.; Sugimori, M.; Llinás, R.; Bezprozvanny, I. *Proc. Nat. Acad. Sci. USA* **2005**, *102*, 2602–2607.
- (19) Sribnick, E. A.; Del Re, A. M.; Ray, S. K.; Woodward, J. J.; Banik, N. L. *Brain Res.* **2009**, *1276*, 159–170.
- (20) Nicholls, D. G.; Ward, M. W. *Trends Neurosci.* **2000**, *23*, 166–174.
- (21) Ward, M. W.; Rego, A. C.; Frenguelli, B. G.; Nicholls, D. G. *J. Neurosci.* **2000**, *20*, 7208–7219.
- (22) Carlberg, I.; Mannervik, B. *Methods Enzymol.* **1985**, *113*, 484–490.
- (23) Pietta, P. G. *J. Nat. Prod.* **2000**, *63*, 1035–1042.

Received February 23, 2023

Revised March 21, 2023

Accepted March 27, 2023